P644: IBRUTINIB DOSE MODIFICATIONS FOR MANAGEMENT OF CARDIAC ADVERSE EVENTS IN PATIENTS WITH B-CELL MALIGNANCIES: POOLED ANALYSIS OF 10 CLINICAL TRIALS

• Deborah Stephens,
• Jennifer R. Brown,
• Shuo MA,
• Michael Wang,
• Carol Moreno,
• Tadeusz Robak,
• Don Stevens,
• Shane Lee,
• Chadi Saifan,
• Emily Hsu,
• Sima Patel,
• Jan Burger

Affiliations

Deborah Stephens

1 Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States

Jennifer R. Brown

2 CLL Center, Dana-Farber Cancer Institute, Boston, MA, United States

Shuo MA

3 Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, United States

Michael Wang

4 The University of Texas MD Anderson Cancer Center, Houston, TX, United States

Carol Moreno

5 Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Josep Carreras Leukaemia Research Institute, Barcelona, Spain

Tadeusz Robak

6 Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland

Don Stevens

7 Norton Cancer Institute, Louisville, KY, United States

Shane Lee

8 Pharmacyclics LLC, an AbbVie Company, North Chicago, IL, United States

Chadi Saifan

8 Pharmacyclics LLC, an AbbVie Company, North Chicago, IL, United States

Emily Hsu

8 Pharmacyclics LLC, an AbbVie Company, North Chicago, IL, United States

Sima Patel

8 Pharmacyclics LLC, an AbbVie Company, North Chicago, IL, United States

Jan Burger

9 Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, United States